Michael J Hawkins

Author PubWeight™ 15.36^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.	J Clin Oncol	2005	2.53
2	A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.	J Exp Ther Oncol	2002	1.68
3	Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.	Cancer Biol Ther	2002	1.50
4	Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.	Clin Cancer Res	2008	1.48
5	Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.	Invest New Drugs	2005	1.40
6	Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.	J Clin Oncol	2008	1.39
7	Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.	Cancer Chemother Pharmacol	2007	1.13
8	Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.	Clin Cancer Res	2009	1.06
9	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.	J Med Chem	2007	0.92
10	Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design.	J Am Chem Soc	2002	0.81
11	Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.	J Clin Oncol	2002	0.80
12	A new family of Fisher-curves estimates Fisher's alpha more accurately.	J Theor Biol	2005	0.77